

SEVERE MUCOCUTANEOUS REACTIONS

- These reactions include paraneoplastic pemphigus, Stevens-Johnson syndrome, lichenoid dermatitis, vesiculobullous dermatitis, and toxic epidermal necrolysis.
- The onset of these reactions varies from 1 to 13 weeks following Rituximab exposure.
- **Discontinue** Rituximab in patients who experience a severe mucocutaneous reaction.
- The safety of readministration of Rituximab to patients with severe mucocutaneous reactions has not been determined.

(1) HIGHLIGHTS OF PRESCRIBING INFORMATION. [cited 2021 Nov 21]; Available from: www.fda.gov/medwatch.

